#obesity drugs
Total 2 articles
EconomyEN
Novo Nordisk Loses $50B in One Day: What's Behind the Obesity Drug Crash?
Danish pharma giant Novo Nordisk saw $50 billion wiped off its market value as competition threatens its dominance in the lucrative obesity drug market.
·
SP
Seoyeon Park
EconomyEN
Novo Nordisk's Cautious 2026 Outlook Signals Obesity Drug Wars Are Just Beginning
Danish pharma giant Novo Nordisk delivered lower-than-expected 2026 guidance, signaling intensifying competition in the obesity drug market as new players challenge Ozempic and Wegovy's dominance.
·
SP
Seoyeon Park